Therapeutics and Clinical Risk Management published a study titled Cannabinoids in the Management of Difficult to Treat Pain, through neurologist and researcher Dr. Ethan Russo.
Cannabinoids were found to bind to areas of the periaqueductal gray matter (an area of the brain that modulates pain transmission) which have been implicated in migraine generation.
Endocannabinoid levels were decreased in patients with chronic migraines suggesting that endocannabinoid dysfunction is involved. Exogenous cannabinoids such as CBD encourage the production of our naturally occurring endocannabinoids.
One of the most common symptoms of a migraine is nausea, pain, sensitivity to light and even vomiting. The British Journal of Pharmacology conducted a study to outline that CBD produces its anti-emetic (antinausea) effect by indirectly activating the somatodendritic 5-HT1a autoreceptor in the dorsal raphe nucleus (DRN).